Search

Displaying results 2121 - 2130 of 6076 in total
  1. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. These trials include NCT03096795 (completed; h...

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    HMR4011

    go.drugbank.com/drugs/DB06225
    Experimental

    IPL 576,092 has previously been investigated as a treatment for asthma.

  3. Drug

    Otenabant

    go.drugbank.com/drugs/DB11745
    Investigational

    Otenabant has been investigated for the treatment of Obesity.

  4. Drug

    Cobalt

    go.drugbank.com/drugs/DB14574
    ApprovedWithdrawn

    Except for radioactive forms of cobalt and cobalamin, the FDA withdrew its approval for the use of drug products containing cobalt salts.[L43942]

  5. Drug

    Sparteine

    go.drugbank.com/drugs/DB06727
    ApprovedWithdrawn

    Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness

  6. Drug

    2,2'-Dibenzothiazyl disulfide

    go.drugbank.com/drugs/DB14201
    Approved

    2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer.

  7. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)

  8. Drug

    Sarafloxacin

    go.drugbank.com/drugs/DB11491
    ApprovedVet approvedWithdrawn

    Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.

  9. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods. … The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis.

  10. Drug

    Histrelin

    go.drugbank.com/drugs/DB06788
    ApprovedInvestigationalWithdrawn

    [L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. … As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700]